

Glenmark's New Molecule Enters Human Trials



NEW DELHI Glenmark Pharmaceuticals on Thursday said its new molecule for potential treatment of autoimmune diseases is entering human trials. Glenmark Pharmaceuticals SA, a wholly-owned Swiss subsidiary of Glenmark Pharmaceuticals, said GBR 830 - a novel monoclonal antibody - is entering human trials. Monoclonal antibodies are produced by a single clone of cells grown in culture to produce unlimited quantities of identical antibodies. They are used in diagnosis, therapy and biotechnology.

R22